StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) company profile

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)

Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –

About Royalty Pharma

Pharmaceutical Preparations, SIC 2834

Royalty Pharma acquires biopharmaceutical royalties and finances life sciences innovation. The company collaborates with academic institutions, non-profit organizations, biotechnology firms, and global pharmaceutical corporations across the biopharmaceutical development spectrum. Its primary offerings comprise third-party royalties on approved medicines, synthetic royalties created on late-stage candidates, and complementary capital arrangements including unsecured debt, equity investments, and launch funding. The company generates receipts from rights tied directly to end-market sales of commercial treatments across diverse therapeutic fields such as rare diseases, oncology, immunology, neuroscience, and respiratory care.

The business manages a portfolio encompassing more than 35 commercial therapies and 20 development-stage candidates. Its underlying royalty agreements grant exposure to global pharmaceutical sales across international territories, including the United States, non-U.S. markets, and early-stage licensing opportunities in China, though certain specific interests exclude territories such as China. The provided text does not identify the location of the company's corporate headquarters.

Summary of the business section of Royalty Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Royalty Pharma plc
Founded
1996
Headquarters
New York, NY
Address
110 East 59th Street 10022
Phone
(212) 883-0200
Employees
100, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
X0
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
RPRX
Exchange
Nasdaq
IPO date
Jun 17, 2020
Shares outstanding
575M, Jul 31, 2026
Public float
$16.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1802768
CUSIP
G7709Q104
FIGI
BBG00V1L5YZ5
Share class FIGI
BBG00V1L5ZR1
LEI
549300FGFN7VOK8BZR03
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Pablo G. LegorretaCEO, Chairman of the Board, Director28,011,146
Marshall UristEVP, Research & Investments1,530,889
Christopher HiteEVP & Chairman, Partnering1,539,512
Terrance P. CoyneEVP & CFO2,096,289
Arthur Richard McGivernEVP, Investments & GC–
George W. LloydEVP, Investments & CLO2,724,616
Bonnie L. BasslerDirector79,823
David C. HodgsonDirector37,873
Elizabeth H. WeathermanDirector13,103
Vlad CoricDirector15,343
Ted W. LoveDirector58,393
Gregory NordenDirector196,348
Carole HoDirector13,103
Catherine M. EngelbertDirector55,673
Henry A. FernandezDirector123,524
Errol B. DesouzaDirector81,352
Pharma plc RoyaltyDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$937.50K$82.51M$1.32M$85$206
FY2024–$191.32M$1.26M$57$170
FY2023–$26.79M$4.56M$61$152
FY2022–$45.76M$4.35M$82$141
FY2021–$57.04M$3.84M$81$128
FY2020–$51.53M$3.46M$113$106

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryTotalvs. prior year
Pablo Legorreta
Chief Executive Officer
$937.50K$937.50K–
Terrance Coyne
Executive Vice President & Chief Financial Officer
$1.32M$1.32M+5%
Christopher Hite
Executive Vice President & Vice Chairman
$1.32M$1.32M+5%
George Lloyd
Senior Advisor; former Executive Vice President, Chief Legal Officer & Investments
$1.32M$1.32M+5%
Marshall Urist, M.D., Ph.D.
Executive Vice President, Research & Investments
$1.32M$1.32M+5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 17, 2020
Offer price
$28.00
Securities offered
77,681,670
Gross proceeds
$2.18B
Exchange
Nasdaq
First trading day
Jun 16, 2020
First-day close
$44.50+58.9%
Lock-up ends (est.)
Dec 13, 2020

“The initial public offering price is $28.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 100 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?